110 related articles for article (PubMed ID: 1512936)
1. [Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases].
Teramoto S; Fukuchi Y; Nagase T; Orimo H
Jpn J Antibiot; 1992 May; 45(5):507-11. PubMed ID: 1512936
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of ciprofloxacin in pulmonary infections in the patients with chronic respiratory diseases].
Kikuchi N; Kawashima T; Yamagishi F; Suzuki K; Yasuda J; Niijima Y; Mizutani F; Tabeta H
Jpn J Antibiot; 1991 Aug; 44(8):839-45. PubMed ID: 1920809
[TBL] [Abstract][Full Text] [Related]
3. [Clinical studies on ciprofloxacin in chronic respiratory tract infection].
Yoshida M; Watanabe K; Tamaru N; Ishibashi T; Takamoto M; Yamada H; Katoh O; Yamaguchi T; Ando M; Matsumoto M
Jpn J Antibiot; 1991 May; 44(5):506-14. PubMed ID: 1880930
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections.
Chono S; Tanino T; Seki T; Morimoto K
Drug Metab Pharmacokinet; 2007 Apr; 22(2):88-95. PubMed ID: 17495415
[TBL] [Abstract][Full Text] [Related]
5. [Clinical studies and sputum levels of ceftriaxone once daily administration in respiratory tract infection].
Kuwabara M; Sasaki H; Fukuhara H; Arita H; Inamizu T; Sadamoto K; Kimura T; Yamane K; Shigemoto M; Kawamoto M
Jpn J Antibiot; 1989 Apr; 42(4):921-9. PubMed ID: 2671426
[TBL] [Abstract][Full Text] [Related]
6. The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections.
Ohmichi M; Hiraga Y
J Int Med Res; 1999; 27(6):297-304. PubMed ID: 10726239
[TBL] [Abstract][Full Text] [Related]
7. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H
Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940
[TBL] [Abstract][Full Text] [Related]
8. [Laboratory and clinical studies on levofloxacin].
Tanaka K; Iwamoto M; Maesaki S; Koga H; Kohno S; Hara K; Sugawara K; Kaku M; Kusano S; Sakito O
Jpn J Antibiot; 1992 May; 45(5):548-56. PubMed ID: 1512941
[TBL] [Abstract][Full Text] [Related]
9. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections.
Chono S; Tanino T; Seki T; Morimoto K
J Control Release; 2008 Apr; 127(1):50-8. PubMed ID: 18230410
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and pharmacokinetics studies of ceftriaxone upon 2g once daily administration in respiratory tract infections].
Ishioka S; Yamakido H; Inyaku K; Hasegawa K; Yamakido M; Akagawa T; Kuwabara M; Kodomari Y; Kawamoto M; Arita H
Jpn J Antibiot; 1991 Jun; 44(6):605-13. PubMed ID: 1890721
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Pedersen SS
Scand J Infect Dis Suppl; 1989; 60():89-97. PubMed ID: 2667111
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and pharmacokinetic study of ciprofloxacin at the level of the respiratory system].
De Rose V; Mangiarotti P; Ferrara AM; Bertoletti R; Grassi G; Manara G; Grassi C
G Ital Chemioter; 1987; 34(1-3):57-61. PubMed ID: 3504415
[No Abstract] [Full Text] [Related]
13. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects.
Chono S; Tanino T; Seki T; Morimoto K
Drug Dev Ind Pharm; 2008 Oct; 34(10):1090-6. PubMed ID: 18777242
[TBL] [Abstract][Full Text] [Related]
14. Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
Scaglione F; Scamazzo F; Arcidiacono MM; Cogo R; Monzani GP; Fraschini F
J Chemother; 1995 Apr; 7(2):140-5. PubMed ID: 7666121
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
[TBL] [Abstract][Full Text] [Related]
16. [Serum and sputum levels of cefotetan used in respiratory tract infections].
Matsumoto Y; Hitsuda Y; Sugimoto Y; Ishikawa J; Sasaki T
Jpn J Antibiot; 1986 Oct; 39(10):2690-4. PubMed ID: 3468274
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of ciprofloxacin on biliary tract infection following oral administration].
Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E
Jpn J Antibiot; 1986 Oct; 39(10):2675-84. PubMed ID: 3806954
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the clinical efficacy and dosage of intravenous ciprofloxacin in patients with respiratory infection.
Matsuo K; Azuma M; Kasai M; Hanji I; Kimura I; Kosugi T; Suga N; Satoh M
J Pharm Pharm Sci; 2009 Jan; 11(2):111s-117s. PubMed ID: 19203473
[TBL] [Abstract][Full Text] [Related]
19. [Serum levels and sputum levels of cefmenoxime in respiratory tract infections].
Matsumoto Y; Ninomaru S; Koshobu T; Ishikawa J; Nakatani S; Sasaki T
Jpn J Antibiot; 1985 Jun; 38(6):1638-42. PubMed ID: 3862881
[TBL] [Abstract][Full Text] [Related]
20. [Ciprofloxacin concentration in human prostatic tissue following 3 days' administration].
Morita M; Nakagawa H; Suzuki K
Hinyokika Kiyo; 1991 May; 37(5):563-6. PubMed ID: 1713402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
